Neoadjuvant GMCI Plus Chemoradiation for Advanced Non-Metastatic Pancreatic Adenocarcinoma
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate Gene Mediated Cytotoxic Immunotherapy (GMCI™) in
combination with standard of care chemoradiation and surgery for borderline resectable and
unresectable locally advanced pancreatic cancer in patients who have completed induction
chemotherapy. GMCI kills tumor cells and creates an immune stimulatory environment in the
tumor. Killing tumor cells in an immune stimulatory environment induces the body's immune
system to detect and destroy cancer cells. GMCI has shown synergy with radiation and surgery
without added toxicity. The hypothesis is that GMCI added to standard of care chemoradiation
and surgery after completion of induction chemotherapy will be safe and will improve the
clinical outcome for patients with pancreatic cancer.